• Acumen Pharmaceuticals Inc has set the terms for its IPO to raise around $125 million to take ACU193, an antibody against amyloid-beta oligomers, to the end of phase 2 in Alzheimer’s disease.

  • Virginia-based Acumen filed with the SEC regulatory filing for its proposed Nasdaq IPO days after the FDA granted accelerated approval to Biogen Inc’s (NASDAQ: BIIB) Aduhelm.

  • The company will trade on NASDAQ under the (NASDAQ: ABOS) symbol.

  • Acumen was initially penciled in to raise $100 million to support the development of the Alzheimer’s candidate.

  • The company has priced its IPO at $14 to $16 a share. If Acumen sells the targeted 8.3 million shares at the midpoint of that range, it will pocket $125 million.

  • Acumen has earmarked $75 million for clinical trials of ACU193.

  • The money will support the phase 1 trial, which is designed to deliver data on safety, tolerability, and clinical proof of mechanism by the end of next year.

  • The company expects to start the phase 2 portion of a phase 2/3 trial in 2023.

See more from Benzinga

  • Click here for options trades from Benzinga

  • Senator Joe Manchin Urges President Biden Not To Nominate Janet Woodcock As FDA Commissioner

  • Biogen Commences Dosing In Late-Stage Systemic Lupus Erythematosus Study With BIIB059

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

(305) 707 0888